<p>Lifecore Biomedical（納斯達克代碼：LFCR - 獲取免費報告）可能將在 4 月 2 日星期四市場收盤後公佈其業績。分析師預計該公司本季度每股收益為（$0.27），收入為 2595.70 萬美元。</p>
<p>Lifecore Biomedical（納斯達克代碼：LFCR - 獲取免費報告）最近一次發佈季度財報是在 3 月 16 日星期一。該公司報告本季度每股收益（EPS）為（$0.16），低於市場共識預期的（$0.11），差距為（$0.05）。該公司本季度收入為 3575 萬美元，高於市場共識預期的 3531 萬美元。Lifecore Biomedical 的股本回報率為負的 1211.09%，淨利潤率為負的 23.08%。分析師平均預計 Lifecore Biomedical 在當前財年每股收益為-$1，在下一個財年每股收益也為-$1。</p>
<p>獲取 <strong>Lifecore Biomedical</strong> 的提醒：</p>
<h2>Lifecore Biomedical 價格表現</h2>
<p>Lifecore Biomedical 的股票在星期五開盤價為$3.87。該公司的債務與股本比率為 113.76，流動比率為 2.80，速動比率為 1.67。Lifecore Biomedical 的股價一年低點為$3.86，一年高點為$8.98。該公司的 50 日簡單移動平均為$6.95，200 日簡單移動平均為$7.29。該股票的市值為 1.4505 億美元，市盈率為-3.95，貝塔值為 0.62。</p>
<h2>機構投資者對 Lifecore Biomedical 的看法</h2>
<p>一些大型投資者最近對 LFCR 的持倉進行了調整。Quarry LP 在第三季度購買了 Lifecore Biomedical 的新股份，價值約為$28,000。BNP Paribas 金融市場在第三季度增持了 Lifecore Biomedical 的股份，增幅為 92.7%。BNP Paribas 金融市場現在擁有 5791 股該公司的股票，價值$43,000，此前在上個季度增持了 2786 股。懷俄明州購買了 Lifecore Biomedical 的新股份，價值為$69,000。製造商人壽保險公司在第二季度購買了 Lifecore Biomedical 的新股份，價值為$88,000。最後，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度增持了 Lifecore Biomedical 的股份，增幅為 14.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在擁有 14785 股該公司的股票，價值為$104,000，此前在此期間增持了 1886 股。當前 83.36% 的股票由機構投資者持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位研究分析師最近對 LFCR 股票發表了評論。Weiss Ratings 在 1 月 22 日的研究報告中重申了對 Lifecore Biomedical 股票的 “賣出（d）” 評級。Barrington Research 在週二重新發布了 “跑贏大盤” 評級，並設定了 Lifecore Biomedical 股票的目標價為$5.50。最後，Zacks Research 在 1 月 1 日的報告中將 Lifecore Biomedical 的股票評級提升至 “持有”。兩位研究分析師給予該股票買入評級，兩位給予持有評級，一位給予賣出評級。根據 MarketBeat.com 的數據，Lifecore Biomedical 的平均評級為 “持有”，共識目標價為$5.50。</p>
<p><strong>查看我們關於 Lifecore Biomedical 的最新報告</strong></p>
<h2>關於 Lifecore Biomedical</h2>
<p>（獲取免費報告）</p>
<p>Lifecore Biomedical, Inc 是一家公開交易的專業生物製藥公司，總部位於明尼蘇達州查斯卡。該公司專注於開發、製造和商業化基於透明質酸（HA）的產品，以滿足醫療和美容需求。Lifecore 的專有 HA 配方旨在滿足高度監管市場對純度、一致性和性能的嚴格監管標準。</p>
<p>該公司的產品組合涵蓋多個治療領域，包括眼科、骨科、皮膚科和傷口護理。</p>
<h2>特色文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Lifecore Biomedical</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZDUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZDUg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Lifecore Biomedical 嗎？</h2>
<p>在你考慮 Lifecore Biomedical 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Lifecore Biomedical 並不在名單上。</p>
<p>雖然 Lifecore Biomedical 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

LFCR

<p>Lifecore Biomedical（納斯達克代碼：LFCR）定於 4 月 2 日星期四市場收盤後發佈財報。分析師預測該季度每股虧損 0.27 美元，收入為 2596 萬美元。該公司此前報告每股虧損 0.16 美元，收入為 3575 萬美元。Lifecore 的市值為 1.4505 億美元，市盈率為-3.95。機構投資者持有 83.36% 的股份，各種分析師的評級從 “買入” 到 “賣出” 不等。平均評級為 “持有”，目標價格為 5.50 美元</p>

<p>Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) will likely be announcing its results after the market closes on Thursday, April 2nd. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $25.9570 million for the quarter.</p>
<div class="lb-trans"><p>Lifecore Biomedical（納斯達克代碼：LFCR - 獲取免費報告）可能將在 4 月 2 日星期四市場收盤後公佈其業績。分析師預計該公司本季度每股收益為（$0.27），收入為 2595.70 萬美元。</p>
</div><p>Lifecore Biomedical (NASDAQ:LFCR - Get Free Report) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05). The company had revenue of $35.75 million for the quarter, compared to the consensus estimate of $35.31 million. Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 23.08%. On average, analysts expect Lifecore Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.</p>
<div class="lb-trans"><p>Lifecore Biomedical（納斯達克代碼：LFCR - 獲取免費報告）最近一次發佈季度財報是在 3 月 16 日星期一。該公司報告本季度每股收益（EPS）為（$0.16），低於市場共識預期的（$0.11），差距為（$0.05）。該公司本季度收入為 3575 萬美元，高於市場共識預期的 3531 萬美元。Lifecore Biomedical 的股本回報率為負的 1211.09%，淨利潤率為負的 23.08%。分析師平均預計 Lifecore Biomedical 在當前財年每股收益為-$1，在下一個財年每股收益也為-$1。</p>
</div><p>Get <strong>Lifecore Biomedical</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Lifecore Biomedical</strong> 的提醒：</p>
</div><h2>Lifecore Biomedical Price Performance</h2>
<div class="lb-trans"><h2>Lifecore Biomedical 價格表現</h2>
</div><p>Shares of Lifecore Biomedical stock opened at $3.87 on Friday. The company has a debt-to-equity ratio of 113.76, a current ratio of 2.80 and a quick ratio of 1.67. Lifecore Biomedical has a one year low of $3.86 and a one year high of $8.98. The business's 50 day simple moving average is $6.95 and its two-hundred day simple moving average is $7.29. The stock has a market capitalization of $145.05 million, a P/E ratio of -3.95 and a beta of 0.62.</p>
<div class="lb-trans"><p>Lifecore Biomedical 的股票在星期五開盤價為$3.87。該公司的債務與股本比率為 113.76，流動比率為 2.80，速動比率為 1.67。Lifecore Biomedical 的股價一年低點為$3.86，一年高點為$8.98。該公司的 50 日簡單移動平均為$6.95，200 日簡單移動平均為$7.29。該股票的市值為 1.4505 億美元，市盈率為-3.95，貝塔值為 0.62。</p>
</div><h2>Institutional Investors Weigh In On Lifecore Biomedical</h2>
<div class="lb-trans"><h2>機構投資者對 Lifecore Biomedical 的看法</h2>
</div><p>A number of large investors have recently made changes to their positions in LFCR. Quarry LP bought a new position in shares of Lifecore Biomedical during the third quarter valued at approximately $28,000. BNP Paribas Financial Markets boosted its holdings in Lifecore Biomedical by 92.7% in the third quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company's stock valued at $43,000 after acquiring an additional 2,786 shares in the last quarter. State of Wyoming bought a new stake in Lifecore Biomedical in the second quarter valued at $69,000. The Manufacturers Life Insurance Company purchased a new position in Lifecore Biomedical during the 2nd quarter valued at $88,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Lifecore Biomedical by 14.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,785 shares of the company's stock valued at $104,000 after purchasing an additional 1,886 shares during the period. 83.36% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些大型投資者最近對 LFCR 的持倉進行了調整。Quarry LP 在第三季度購買了 Lifecore Biomedical 的新股份，價值約為$28,000。BNP Paribas 金融市場在第三季度增持了 Lifecore Biomedical 的股份，增幅為 92.7%。BNP Paribas 金融市場現在擁有 5791 股該公司的股票，價值$43,000，此前在上個季度增持了 2786 股。懷俄明州購買了 Lifecore Biomedical 的新股份，價值為$69,000。製造商人壽保險公司在第二季度購買了 Lifecore Biomedical 的新股份，價值為$88,000。最後，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度增持了 Lifecore Biomedical 的股份，增幅為 14.6%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.現在擁有 14785 股該公司的股票，價值為$104,000，此前在此期間增持了 1886 股。當前 83.36% 的股票由機構投資者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several research analysts recently commented on LFCR shares. Weiss Ratings reaffirmed a &#34;sell (d)&#34; rating on shares of Lifecore Biomedical in a research note on Thursday, January 22nd. Barrington Research reissued an &#34;outperform&#34; rating and set a $5.50 price target on shares of Lifecore Biomedical in a research report on Tuesday. Finally, Zacks Research raised shares of Lifecore Biomedical to a &#34;hold&#34; rating in a report on Thursday, January 1st. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Lifecore Biomedical has an average rating of &#34;Hold&#34; and a consensus target price of $5.50.</p>
<div class="lb-trans"><p>幾位研究分析師最近對 LFCR 股票發表了評論。Weiss Ratings 在 1 月 22 日的研究報告中重申了對 Lifecore Biomedical 股票的 “賣出（d）” 評級。Barrington Research 在週二重新發布了 “跑贏大盤” 評級，並設定了 Lifecore Biomedical 股票的目標價為$5.50。最後，Zacks Research 在 1 月 1 日的報告中將 Lifecore Biomedical 的股票評級提升至 “持有”。兩位研究分析師給予該股票買入評級，兩位給予持有評級，一位給予賣出評級。根據 MarketBeat.com 的數據，Lifecore Biomedical 的平均評級為 “持有”，共識目標價為$5.50。</p>
</div><p><strong>View Our Latest Report on Lifecore Biomedical</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Lifecore Biomedical 的最新報告</strong></p>
</div><h2>About Lifecore Biomedical</h2>
<div class="lb-trans"><h2>關於 Lifecore Biomedical</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.</p>
<div class="lb-trans"><p>Lifecore Biomedical, Inc 是一家公開交易的專業生物製藥公司，總部位於明尼蘇達州查斯卡。該公司專注於開發、製造和商業化基於透明質酸（HA）的產品，以滿足醫療和美容需求。Lifecore 的專有 HA 配方旨在滿足高度監管市場對純度、一致性和性能的嚴格監管標準。</p>
</div><p>The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.</p>
<div class="lb-trans"><p>該公司的產品組合涵蓋多個治療領域，包括眼科、骨科、皮膚科和傷口護理。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Lifecore Biomedical</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Lifecore Biomedical</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TEZDUg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=LFCR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lifecore Biomedical Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Lifecore Biomedical 嗎？</h2>
</div><p>Before you consider Lifecore Biomedical, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Lifecore Biomedical 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lifecore Biomedical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Lifecore Biomedical 並不在名單上。</p>
</div><p>While Lifecore Biomedical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Lifecore Biomedical 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Lifecore Biomedical (LFCR) 將在週四公佈財報